Biotech · Private company
Pluristem Ltd.
Track this companyFree. Adds Pluristem Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials60 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- PLX-PADPhase 3 · Critical Limb Ischemia (CLI)ClinicalTrials.gov · fetched Nov 12, 2026
- PLX-PADPhase 3 · Hip FractureClinicalTrials.gov · fetched Nov 12, 2026
- PLX-PADPhase 2 · COVIDClinicalTrials.gov · fetched Nov 12, 2026
- PLX-PAD high dosesPhase 2 · Intermittent ClaudicationClinicalTrials.gov · fetched Nov 12, 2026
- PLX-PAD Low dosePhase 2 · Intermittent ClaudicationClinicalTrials.gov · fetched Nov 12, 2026
- PLX-R18Phase 1 · Incomplete HCT (Hematopoietic Cell Transplantation)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19PHASE2 · TERMINATED · started Oct 1, 2020ClinicalTrials.gov NCT04389450 · fetched Nov 12, 2026
- Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)PHASE3 · COMPLETED · started Jul 26, 2018ClinicalTrials.gov NCT03451916 · fetched Nov 12, 2026
- Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for RevascularizationPHASE3 · COMPLETED · started May 22, 2017ClinicalTrials.gov NCT03006770 · fetched Nov 12, 2026
- Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell TransplantationPHASE1 · COMPLETED · started Feb 8, 2017ClinicalTrials.gov NCT03002519 · fetched Nov 12, 2026
- Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)PHASE2 · COMPLETED · started Nov 5, 2012ClinicalTrials.gov NCT01679990 · fetched Nov 12, 2026
- Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for RevascularizationNO_LONGER_AVAILABLEClinicalTrials.gov NCT03886506 · fetched Nov 12, 2026